Aorta-CAD vs iPredict Eye Screening

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

Aorta-CAD

by Imagen Technologies

iPredict Eye Screening

by iHealthScreen

AI Verdict

Aorta-CAD is designed to assist physicians in detecting aortic atherosclerosis and ectasia on chest X-rays, focusing on diagnostic imaging for specific cardiovascular conditions. In contrast, iPredict Eye Screening provides AI-powered screening for ophthalmic diseases like diabetic retinopathy, AMD, and glaucoma using retinal imaging, and also offers risk prediction for systemic conditions such as stroke and heart attack. While both are FDA-cleared, cloud-based AI tools that touch upon cardiovascular health, they utilize different imaging modalities and target distinct primary clinical applications.

Choose Aorta-CAD if…

Choose Aorta-CAD if your practice frequently utilizes chest X-rays and you aim to augment physician accuracy in identifying signs of Aortic Atherosclerosis and Aortic Ectasia. This cloud-based AI seamlessly integrates into existing radiology workflows, providing an overlay to assist radiologists and primary care physicians in reducing misses for these critical aortic conditions.

View Aorta-CAD →

Choose iPredict Eye Screening if…

Choose iPredict Eye Screening if your clinic requires a rapid, AI-powered solution for comprehensive screening of age-related macular degeneration, diabetic retinopathy, and glaucoma. This tool is ideal for primary care or ophthalmology settings seeking to quickly identify patients at risk for these retinal diseases, while also offering valuable insights into systemic disease risk like stroke and heart attack.

View iPredict Eye Screening →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	Aorta-CAD	iPredict Eye Screening
Pricing	Contact for pricing	Contact for pricing
Deployment	Cloud-based	Cloud-based (Software as a Medical Device), accessible in primary care settings, clinics, hospitals, and online for telemedicine and prediction apps.
BAA Available	Yes AI-estimated	Unknown
FDA Status	Cleared AI-estimated	Cleared AI-estimated
HIPAA	Yes AI-estimated	Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

iPredict Eye Screening

Tool B emphasizes an 'easy to operate, non-invasive, with an advanced touchscreen interface' and 'fast results: test completed in less than 5 minutes, report in under 60 seconds'. This suggests a highly intuitive and efficient user experience, particularly for point-of-care settings. While Tool A focuses on seamless integration into existing workflows, Tool B's explicit mention of speed and a user-friendly interface gives it a slight edge in direct usability.

Clinical Value

iPredict Eye Screening

Tool B offers AI-powered screening for three major ocular diseases (AMD, DR, Glaucoma) and provides 'risk prediction for systemic diseases like stroke and heart attack', broadening its clinical impact beyond a single specialty. It also provides specific accuracy metrics (e.g., AMD sensitivity 86.86%, specificity 94.13%). Tool A focuses on two specific aortic conditions with demonstrated relative reductions in misses, which is valuable, but Tool B's multi-disease screening and systemic risk prediction offer a more comprehensive clinical value proposition.

Pricing & Value

iPredict Eye Screening

Tool B provides an estimated pricing model of '$10-$20 per patient' on a SaaS model, explicitly linking it to '20%-40% of Medicare/commercial payor reimbursement'. This level of transparency allows potential customers to better assess the financial value and integrate it into their budgeting. Tool A only states 'contact for pricing', offering no immediate insight into its cost structure.

Enterprise Readiness

iPredict Eye Screening

Both tools are FDA-cleared, HIPAA compliant, and cloud-based. Tool B explicitly highlights 'Electronic Health Record (EHR) Solutions' and accessibility in diverse settings including 'primary care settings, clinics, hospitals, and online for telemedicine and prediction apps'. This broad integration and deployment flexibility suggest a higher degree of readiness for varied enterprise environments. While Tool A has a BAA, Tool B's explicit EHR integration and wider deployment scope are key for enterprise adoption.

Innovation

iPredict Eye Screening

Tool B demonstrates broader innovation by combining AI-based screening for multiple ocular diseases with 'risk prediction for systemic diseases like stroke and heart attack' and 'AI-Based Telemedicine Service'. This multi-faceted approach extends beyond a single diagnostic aid to encompass preventative health and remote care. Tool A, while innovative in its deep learning application for specific aortic conditions, is more focused on a singular diagnostic assistance task.

Support & Docs

Tie

Neither the provided structured facts nor general web searches yielded specific, publicly available information regarding the depth or accessibility of support and documentation for either Aorta-CAD or iPredict Eye Screening. Without further details, it is not possible to distinguish between the two on this dimension.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	Aorta-CAD	iPredict Eye Screening
Name	Aorta-CAD	iPredict Eye Screening
Company	Imagen Technologies	iHealthScreen
Description	FDA-cleared, cloud-based AI software that assists physicians in detecting signs of Aortic Atherosclerosis and Aortic Ectasia on chest X-rays, integrating seamlessly into existing workflows.	FDA-cleared AI-powered screening tool for age-related macular degeneration (AMD) in patients aged 50 years and older, alongside screening for Diabetic Retinopathy (DR) and Glaucoma. The platform also provides risk prediction for systemic diseases like stroke and heart attack, integrating with EHR and telemedicine services.
Primary Detections/Screenings	Aortic Atherosclerosis and Aortic Ectasia on chest X-rays	Diabetic Retinopathy (DR), Age-related Macular Degeneration (AMD), Glaucoma, and risk prediction for stroke and heart attack.
Specialties	Cardiology, Internal Medicine, Radiology	Family Medicine, Internal Medicine, Ophthalmology

Videos

Demos, reviews, and walkthroughs featuring Aorta-CAD and iPredict Eye Screening.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

How does each tool specifically integrate into existing clinical workflows, and what is the expected impact on physician interpretation time and diagnostic confidence?

Aorta-CAD is designed to seamlessly integrate into existing X-ray reading workflows, creating togglable annotations to assist physicians in interpreting chest X-rays. iPredict Eye Screening is easy to operate, non-invasive, and provides fast results, with tests completed in under 5 minutes and reports in under 60 seconds, making it accessible in various primary care settings.

What is the specific depth of EHR integration offered by each tool, particularly concerning automated data transfer of findings and reports into patient records?

Aorta-CAD integrates seamlessly into existing workflows, implying data flow, but specific details on automated transfer to EHR are not provided. iPredict Eye Screening explicitly offers Electronic Health Record (EHR) Solutions, indicating a direct integration capability for managing patient data.

How do the reported accuracy metrics (e.g., relative reduction in misses for Aorta-CAD vs. sensitivity/specificity for iPredict) translate into practical clinical utility and diagnostic confidence for their respective target conditions?

Aorta-CAD demonstrated a 62% relative reduction in misses for aortic calcification and a 35% relative reduction in misses for dilated aorta in clinical studies, enhancing detection of these conditions on chest X-rays. iPredict Eye Screening boasts high accuracy, approximately 95% on average, with AMD sensitivity at 86.86% and specificity at 94.13%, providing reliable screening for retinal diseases.

For a general internal medicine or family medicine practice, which tool offers a broader or more immediately applicable scope of clinical utility, considering Aorta-CAD's focus on chest X-rays versus iPredict's multi-disease eye screening and systemic risk prediction?

Aorta-CAD assists in detecting aortic atherosclerosis and ectasia from routine chest X-rays, relevant for cardiovascular risk assessment in internal medicine. iPredict Eye Screening offers broader utility by screening for Diabetic Retinopathy, AMD, and Glaucoma, and provides risk prediction for systemic diseases like stroke and heart attack, making it valuable for comprehensive preventive care in primary care.

What kind of support and training are provided to ensure a smooth learning curve and effective adoption of the AI tools within a busy clinical environment?

While specific training details are not provided, Aorta-CAD emphasizes seamless integration into existing workflows, suggesting a design aimed at minimizing disruption. iPredict Eye Screening highlights its ease of operation and advanced touchscreen interface, which could contribute to a smoother learning curve for clinical staff.

Beyond standard compliance, what specific measures are in place to ensure the security and integrity of patient data, and what audit-trail features are available for tracking AI-assisted diagnoses?

The provided information confirms both tools are HIPAA compliant, but does not detail additional security measures beyond this standard or specific audit-trail features for tracking AI-assisted diagnoses.